Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.450
-0.140 (-8.80%)
Apr 1, 2025, 11:03 AM EDT - Market open

Skye Bioscience Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Net Income
-26.57-37.64-19.48-8.52-6.56
Upgrade
Depreciation & Amortization
0.30.120.110.030
Upgrade
Other Amortization
0.60.330.490.590.54
Upgrade
Loss (Gain) From Sale of Assets
-1.350.3---
Upgrade
Asset Writedown & Restructuring Costs
-21.22---
Upgrade
Stock-Based Compensation
8.320.990.630.870.3
Upgrade
Other Operating Activities
-3.911.26.27-0.1-0.44
Upgrade
Change in Accounts Payable
-0.59-0.70.80.520.24
Upgrade
Change in Other Net Operating Assets
-2.040.23-1.560.13-0.15
Upgrade
Operating Cash Flow
-25.24-13.95-12.74-6.47-6.05
Upgrade
Capital Expenditures
-1.6-0.01-0.09-0.09-0.01
Upgrade
Sale of Property, Plant & Equipment
1.365.53---
Upgrade
Cash Acquisitions
-1.085.31--
Upgrade
Investing Cash Flow
-0.256.65.21-0.09-0.01
Upgrade
Short-Term Debt Issued
-4.97---
Upgrade
Long-Term Debt Issued
--0.68-0.57
Upgrade
Total Debt Issued
-4.970.68-0.57
Upgrade
Long-Term Debt Repaid
--0.26-0.89--
Upgrade
Net Debt Issued (Repaid)
-4.71-0.21-0.57
Upgrade
Issuance of Common Stock
9012014.016.99
Upgrade
Other Financing Activities
-6.43-0.27--0.94-0.85
Upgrade
Financing Cash Flow
83.5616.44-0.2113.086.7
Upgrade
Net Cash Flow
58.089.09-7.746.510.64
Upgrade
Free Cash Flow
-26.84-13.96-12.84-6.57-6.06
Upgrade
Free Cash Flow Per Share
-0.74-1.99-5.78-4.04-6.55
Upgrade
Cash Interest Paid
0.430.20.330.040.12
Upgrade
Cash Income Tax Paid
0.0100.0100
Upgrade
Levered Free Cash Flow
-9.05-11.04-9.44-3.28-3.81
Upgrade
Unlevered Free Cash Flow
-9.18-10.8-9.51-3.39-3.91
Upgrade
Change in Net Working Capital
-2.683.45-1.29-0.70.28
Upgrade
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q